Contineum Therapeutics, Inc.
$13.47
▼
-0.07%
2026-04-21 06:16:01
www.contineum-tx.com
NMS: CTNM
Explore Contineum Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$524.38 M
Current Price
$13.47
52W High / Low
$16.33 / $3.35
Stock P/E
—
Book Value
$6.99
Dividend Yield
—
ROCE
-25.5%
ROE
-26.13%
Face Value
—
EPS
$-2.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
51
Beta
1.39
Debt / Equity
3.16
Current Ratio
27.5
Quick Ratio
27.5
Forward P/E
-5.92
Price / Sales
—
Enterprise Value
$225.87 M
EV / EBITDA
-3.33
EV / Revenue
—
Rating
None
Target Price
$22
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 2. | MindWalk Holdings Corp. | $1.27 | — | $59.32 M | — | -34.42% | -58.82% | $3.25 / $0.4 | $0.23 |
| 3. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
| 4. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
| 5. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 6. | Codexis, Inc. | $2.62 | — | $235.35 M | — | -31.3% | -74.88% | $3.87 / $0.96 | $0.56 |
| 7. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -17.11 M | -14.93 M | -17.9 M | -18.11 M | -17.05 M | — |
| Net Profit | -15.16 M | -12.79 M | -16.04 M | -15.99 M | -14.56 M | — |
| EPS in Rs | -0.46 | -0.39 | -0.49 | -0.49 | -0.45 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 50 M | 0 M |
| Operating Profit | -68.06 M | -50.89 M | 16.08 M | -22.72 M |
| Net Profit | -59.98 M | -42.26 M | 22.72 M | -24.25 M |
| EPS in Rs | -1.84 | -1.29 | 0.7 | -0.74 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 276.64 M | 212.85 M | 130.39 M | 50.64 M |
| Total Liabilities | 15.65 M | 14.78 M | 198.32 M | 143.85 M |
| Equity | 260.99 M | 198.07 M | -67.94 M | -93.21 M |
| Current Assets | 267.92 M | 206.39 M | 127.71 M | 48.39 M |
| Current Liabilities | 9.74 M | 9.97 M | 5.48 M | 7.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -55.31 M | -32.84 M | 19.35 M | -20.12 M |
| Investing CF | -3.71 M | -69.74 M | -65.57 M | 22.3 M |
| Financing CF | 112.69 M | 109 M | 56.18 M | -1.24 M |
| Free CF | -55.54 M | -33.36 M | 18.93 M | -20.24 M |
| Capex | -0.23 M | -0.51 M | -0.41 M | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | -285.99% | 193.68% | — | — |
| Profit Margin % | — | 45.44% | — | — |
| Operating Margin % | — | 32.15% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | 47.15% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.